Claims for Patent: 7,033,596
✉ Email this page to a colleague
Summary for Patent: 7,033,596
| Title: | Transformant for screening of inhibitors for human immunodeficiency virus |
| Abstract: | A microorganism cotransformed with a gene expressing HIV nucleocapsid protein and a plasmid vector containing HIV ψ gene and β-galactosidase reporter gene, and a method for screening HIV inhibitors employing the transformant. The invented method comprising the steps of culturing the transformant, treating it with putative compounds or compositions of HIV inhibitors, and measuring the degree of change in β-galactosidase expression in the culture, can be practically applied in screening HIV packaging inhibitors by which the interaction between HIV nucleocapsid and HIV ψ sequence is blocked. |
| Inventor(s): | Hyuk-Jun Nam, Sang-Hern Kim |
| Assignee: | YOU JI-CHANG , JI CHANG YOU |
| Application Number: | US10/009,118 |
Details for Patent 7,033,596
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | July 25, 2003 | ⤷ Get Started Free | 2020-10-18 |
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | April 12, 2006 | ⤷ Get Started Free | 2020-10-18 |
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | July 03, 2007 | ⤷ Get Started Free | 2020-10-18 |
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | July 12, 2012 | ⤷ Get Started Free | 2020-10-18 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch